IMVT vs UDR · $2.90B cap vs P/E 26, rev $1.71B
Immunovant Inc (IMVT) versus UDR Inc (UDR) — a side-by-side from cached financials, not a winner call.
Immunovant Inc (IMVT) is a biotechnology company listed on US.
UDR Inc (UDR) is a reit - residential company listed on NYSE.
IMVT does not have a complete income-statement cache yet.
Latest reported UDR revenue for 2025-12-31 was $1.71B. Net income was $377.7M. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. UDR currently screens at market cap $13.95B and trailing P/E 25.6.
IMVT currently screens at market cap $2.90B. UDR currently screens at market cap $13.95B and trailing P/E 25.6.
Not investment advice. Open the IMVT and UDR stock pages for the full models.
Not investment advice.